Baxter has launched ready-to-use Vancomycin Injection in 0.9% Sodium Chloride (Normal Saline) in 500mg, 750mg and 1g presentations. 

RELATED: AKI Incidence Compared in Vancomycin Combo Therapies

The launch is an extension of Baxter’s existing Vancomycin injection in 5% dextrose in 500mg, 750mg and 1g presentations and provides an alternative to certain patients who may need to avoid receiving additional dextrose. 

Vancomycin Injection, a tricyclic glycopeptide antibiotic, is indicated for the treatment of serious or severe infections due to susceptible methicillin-resistant (beta-lactam-resistant) staphylococci in penicillin-allergic patients; patients who cannot receive or have failed to respond to other drugs, including penicillins and cephalosporins; and for infections due to vancomycin-susceptible organisms resistant to other antimicrobials. 

Continue Reading

It is also used to treat Staphylococcal endocarditis, including septicemia, and infections of the lower respiratory tract, bone, and skin and skin structure; Streptococcal endocarditis due to Sviridans or S.bovis as monotherapy or in combination with an aminoglycoside; Enterococcal endocarditis due to E. faecalis in combination with an aminoglycoside; Diphtheroid endocarditis; early-onset prosthetic valve endocarditis due to Sepidermidisor diphtheroids in combination with rifampin, or an aminoglycoside, or both.

For more information call (224) 948-5353 or visit